CovInnovations.com

We have a near cure for late stage COVID-19. 93.6% survival rate in statistically significant study.

Mission Statement: CovInnovations is a company created to bring to market three COVID-19-related
technologies: a successful treatment, a 2-minute RNA test and a susceptibility test. Company efforts
have focused primarily on the treatment, since of the three technologies this has the greatest potential
for social and financial benefit in the shortest amount of time.
The Problem: COVID-19 infection has two stages. The first stage is viral replication for which many drugs
have been shown to provide benefit. Most people survive the first stage without serious incident. A
small percentage go on to the second stage which is characterized by an overactive immune response
referred to as a cytokine storm that often leads to death. There is no effective therapeutic available to
treat COVID-19 in adults after the inflammatory phase of the disease takes hold other than dexamethasone,
which provides mild benefit.
The Solution: We identified a drug which appears to terminate the cytokine storm by suppressing IL-6
activity. A retrospective study demonstrated a 68% reduction in mortality (p<0.05) and a 37% reduction
in length of hospital stay (p<0.01). The treated group and the control group both received standard of
care treatment as of 6/2020. Patients in the group provided the drug had a 93.6% survival rate as
compared to the control group which had a survival rate of 78.5%.  We added a second drug to improve
performance, applied for a patent and hired FDA consultants to assist with the FDA Emergency Use
Authorizaton process. There is nothing else like this available. We trademarked the name CovArrest.
Path to Revenue: We applied for patents and added a second drug which should act synergistically and
thus improve survival rates. We have had our science reviewed favorably by professors and graduates of
top US universities. We have written a randomized controlled trial protocol in coordination with a
Harvard-trained immunology professor from South America. We have engaged FDA consultants who are
guiding us through the FDA emergency use authorization process and providing advice on trial design.
We are in the process of preparing our pre-IND letter. We are simultaneously pursuing approval in
foreign countries recently hard-hit by COVID-19 with the assistance of one of our board members who
formerly worked with US Commercial Services. We have engaged attorneys with specific expertise in
pharmaceutical IP law, international commerce regulation, SEC oversight, and pharmaceutical
contracting. One mentor is a CEO of a pharmaceutical company and who previously helped get
cyclosporin through the FDA. We are in negotiations with a contract manufacturing pharmacy to
produce the drug in the US for export.
Valuation: Our target US price for a 10-day course of treatment for this life-saving drug with no
competitors we feel should be on par with the price of recombinant factor 7, about $8000. In third
world countries the price may be $1000 - $2000. If we can sell at this price to 10% of the people who
need the drug (estimated at 6x the death rate) gross sales would be about $2,000,000,000. This would
create a valuation for the company of at least $1BB. If the other technologies are developed, additional
revenue can be generated.